Drugs / INCB081776
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06308913 | Sep 2024 → Oct 2026 expected | head and neck squamous cell carcinoma | University of Wisconsin, Madison | Active not recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT03522142 | Aug 2018 → Sep 2025 | cancer | Incyte Corporation | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INCB081776 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06308913 ↗ |
| Route | Oral | “administered once or twice daily orally” NCT03522142 ↗ |